Intelligent Investor

Prospa Group Limited (ASX: PGL) - Announcements

- Current share price for PGL : $0.410

ASX company news and announcements for Prospa Group Limited (PGL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Prospa Group Limited (PGL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Prospa Group Limited (PGL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Prospa Group Limited (PGL)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
$67 Trading Halt 18 Dec 2006 9:48AM n/a $0.410 $0.425 n/a
$67 Open Briefing.Progen.CEO on Phase 2 Preliminary Results 13 Dec 2006 12:02PM $4.990 $0.410 $0.425 fallen by 91.78%
$67 Positive Results for Phase 2 Liver Cancer Trial 13 Dec 2006 9:33AM $4.990 $0.410 $0.425 fallen by 91.78%
$67 Trading Halt 12 Dec 2006 2:09PM $4.150 $0.410 $0.425 fallen by 90.12%
$67 FDA Provides Manufacturing Clearance for Phase III Trial 29 Nov 2006 10:07AM $3.850 $0.410 $0.425 fallen by 89.35%
$67 Response to ASX Query 30 Oct 2006 10:10AM $3.400 $0.410 $0.425 fallen by 87.94%
$67 Preliminary Final Report/Full Year Accounts 31 Aug 2006 10:23AM $2.600 $0.410 $0.425 fallen by 84.23%
$67 Accelerated Clinical Development of PI-88 post FDA meeting 16 May 2006 8:30AM $3.850 $0.410 $0.425 fallen by 89.35%
$67 Meets with FDA to progress PI-88 clinical development 27 Mar 2006 10:22AM $3.460 $0.410 $0.425 fallen by 88.15%
$67 Half Yearly Report & Half Year Accounts 14 Mar 2006 7:07PM $3.080 $0.410 $0.425 fallen by 86.69%
$67 Discovery of a Novel Class of Compounds 14 Nov 2005 10:40AM $3.170 $0.410 $0.425 fallen by 87.07%
$67 Preliminary Final Report & Full Year Accounts 5 Sep 2005 10:40AM $2.570 $0.410 $0.425 fallen by 84.05%
$67 Open Briefing PGL New Phase II Prostate Cancer Trial&Update 15 Aug 2005 10:12AM $2.750 $0.410 $0.425 fallen by 85.09%
$67 Expand PI-88 Clinical Development to Prostate Cancer 9 Aug 2005 8:30AM $2.990 $0.410 $0.425 fallen by 86.29%
$67 Offered Ausindustry Commercial Ready Grant 25 Jul 2005 9:50AM $2.730 $0.410 $0.425 fallen by 84.98%
$67 Response to ASX Query - Share Price 2 Jun 2005 5:47PM $2.100 $0.410 $0.425 fallen by 80.48%
$67 Response to ASX Query re: Share Price 9 Mar 2005 9:36AM $3.300 $0.410 $0.425 fallen by 87.58%
$67 Progen Extends PI-88 Melanoma Clinical Program 2 Feb 2005 10:55AM $4.550 $0.410 $0.425 fallen by 90.99%
$67 Response to ASX Price Query 4 Aug 2004 11:56AM $4.080 $0.410 $0.425 fallen by 89.95%
$67 US FDA Orphan Drug Status to PI-88 for Melanoma 4 May 2004 9:19AM $3.650 $0.410 $0.425 fallen by 88.77%
$67 Half Year Results & Encouragement from Avastin's Approval 27 Feb 2004 3:29PM $1.800 $0.410 $0.425 fallen by 77.22%
$67 Half Yearly Report 27 Feb 2004 3:28PM $1.800 $0.410 $0.425 fallen by 77.22%
$67 Commences Third PI-88 Phase II Trial 11 Feb 2004 10:37AM $1.590 $0.410 $0.425 fallen by 74.21%
$67 PI-88 Melanoma Phase II trial commenced 21 Jan 2004 10:58AM $1.660 $0.410 $0.425 fallen by 75.30%
$67 Bonus Issue of Options - Record Date 28/11/2003 19 Nov 2003 11:26AM $1.400 $0.410 $0.425 fallen by 70.71%

476 - 500 of 506 results

Page 20 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.